Annual Current Liabilities
$103.17 M
-$2.29 M-2.17%
September 30, 2024
Summary
- As of February 7, 2025, ARWR annual total current liabilities is $103.17 million, with the most recent change of -$2.29 million (-2.17%) on September 30, 2024.
- During the last 3 years, ARWR annual current liabilities has fallen by -$43.37 million (-29.60%).
- ARWR annual current liabilities is now -29.60% below its all-time high of $146.54 million, reached on September 30, 2021.
Performance
ARWR Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$103.17 M
+$6.45 M+6.67%
September 30, 2024
Summary
- As of February 7, 2025, ARWR quarterly total current liabilities is $103.17 million, with the most recent change of +$6.45 million (+6.67%) on September 30, 2024.
- Over the past year, ARWR quarterly current liabilities has increased by +$37.99 million (+58.29%).
- ARWR quarterly current liabilities is now -47.21% below its all-time high of $195.43 million, reached on June 30, 2021.
Performance
ARWR Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
ARWR Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -2.2% | +58.3% |
| 3 y3 years | -29.6% | -29.6% |
| 5 y5 years | +6.3% | -29.6% |
ARWR Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.6% | at low | -25.7% | +61.9% |
| 5 y | 5-year | -29.6% | +153.6% | -47.2% | +311.1% |
| alltime | all time | -29.6% | >+9999.0% | -47.2% | >+9999.0% |
Arrowhead Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | $103.17 M(-2.2%) | $103.17 M(+6.7%) |
| Jun 2024 | - | $96.71 M(+48.4%) |
| Mar 2024 | - | $65.17 M(+2.3%) |
| Dec 2023 | - | $63.72 M(-39.6%) |
| Sep 2023 | $105.46 M(-24.1%) | $105.46 M(+50.2%) |
| Jun 2023 | - | $70.23 M(-19.4%) |
| Mar 2023 | - | $87.15 M(-28.6%) |
| Dec 2022 | - | $122.01 M(-12.1%) |
| Sep 2022 | $138.85 M(-5.2%) | $138.85 M(+8.3%) |
| Jun 2022 | - | $128.21 M(-7.7%) |
| Mar 2022 | - | $138.86 M(+1.3%) |
| Dec 2021 | - | $137.03 M(-6.5%) |
| Sep 2021 | $146.54 M(+260.2%) | $146.54 M(-25.0%) |
| Jun 2021 | - | $195.43 M(+16.9%) |
| Mar 2021 | - | $167.19 M(+566.2%) |
| Dec 2020 | - | $25.09 M(-38.3%) |
| Sep 2020 | $40.68 M(-58.1%) | $40.68 M(-4.9%) |
| Jun 2020 | - | $42.78 M(-19.8%) |
| Mar 2020 | - | $53.33 M(-27.6%) |
| Dec 2019 | - | $73.70 M(-24.1%) |
| Sep 2019 | $97.07 M(+685.0%) | $97.07 M(+11.5%) |
| Jun 2019 | - | $87.09 M(-14.5%) |
| Mar 2019 | - | $101.81 M(-24.4%) |
| Dec 2018 | - | $134.61 M(+988.7%) |
| Sep 2018 | $12.37 M(-33.9%) | $12.37 M(+73.5%) |
| Jun 2018 | - | $7.13 M(-21.9%) |
| Mar 2018 | - | $9.12 M(-33.5%) |
| Dec 2017 | - | $13.72 M(-26.7%) |
| Sep 2017 | $18.70 M(-27.1%) | $18.70 M(-8.0%) |
| Jun 2017 | - | $20.32 M(-26.2%) |
| Mar 2017 | - | $27.55 M(-25.5%) |
| Dec 2016 | - | $37.00 M(+44.3%) |
| Sep 2016 | $25.64 M(+61.3%) | $25.64 M(+72.8%) |
| Jun 2016 | - | $14.84 M(+5.6%) |
| Mar 2016 | - | $14.06 M(+14.0%) |
| Dec 2015 | - | $12.33 M(-22.5%) |
| Sep 2015 | $15.90 M(+34.2%) | $15.90 M(+66.8%) |
| Jun 2015 | - | $9.53 M(-27.8%) |
| Mar 2015 | - | $13.21 M(+14.9%) |
| Dec 2014 | - | $11.50 M(-2.9%) |
| Sep 2014 | $11.85 M(+35.8%) | $11.85 M(+43.6%) |
| Jun 2014 | - | $8.25 M(-21.3%) |
| Mar 2014 | - | $10.48 M(+16.2%) |
| Dec 2013 | - | $9.02 M(+3.4%) |
| Sep 2013 | $8.72 M(+63.8%) | $8.72 M(+30.7%) |
| Jun 2013 | - | $6.68 M(-6.8%) |
| Mar 2013 | - | $7.16 M(+17.9%) |
| Dec 2012 | - | $6.08 M(+14.1%) |
| Sep 2012 | $5.33 M | $5.33 M(-8.4%) |
| Jun 2012 | - | $5.82 M(-8.8%) |
| Mar 2012 | - | $6.38 M(+26.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | - | $5.06 M(+96.0%) |
| Sep 2011 | $2.58 M(-39.6%) | $2.58 M(+19.5%) |
| Jun 2011 | - | $2.16 M(-13.4%) |
| Mar 2011 | - | $2.49 M(-68.4%) |
| Dec 2010 | - | $7.90 M(+84.8%) |
| Sep 2010 | $4.28 M(+82.4%) | $4.28 M(-16.8%) |
| Jun 2010 | - | $5.14 M(+125.5%) |
| Mar 2010 | - | $2.28 M(-11.6%) |
| Dec 2009 | - | $2.58 M(+10.1%) |
| Sep 2009 | $2.34 M(-37.1%) | $2.34 M(-31.3%) |
| Jun 2009 | - | $3.41 M(-23.4%) |
| Mar 2009 | - | $4.45 M(-8.5%) |
| Dec 2008 | - | $4.86 M(+30.4%) |
| Sep 2008 | $3.73 M(+28.7%) | $3.73 M(+45.8%) |
| Jun 2008 | - | $2.56 M(+11.4%) |
| Mar 2008 | - | $2.29 M(+0.4%) |
| Dec 2007 | - | $2.28 M(-21.2%) |
| Sep 2007 | $2.90 M(-0.8%) | $2.90 M(-1.5%) |
| Jun 2007 | - | $2.94 M(+156.5%) |
| Mar 2007 | - | $1.15 M(+12.9%) |
| Dec 2006 | - | $1.02 M(-65.2%) |
| Sep 2006 | $2.92 M(+185.1%) | $2.92 M(+68.9%) |
| Jun 2006 | - | $1.73 M(-33.2%) |
| Mar 2006 | - | $2.59 M(+77.8%) |
| Dec 2005 | - | $1.46 M(+42.2%) |
| Sep 2005 | $1.02 M(+48.5%) | $1.02 M(+3.2%) |
| Jun 2005 | - | $992.70 K(+71.4%) |
| Mar 2005 | - | $579.20 K(+64.6%) |
| Dec 2004 | - | $351.90 K(-49.0%) |
| Sep 2004 | $689.70 K(+616.9%) | $689.70 K(+84.9%) |
| Jun 2004 | - | $373.00 K(+871.4%) |
| Mar 2004 | - | $38.40 K(+89.2%) |
| Dec 2003 | - | $20.30 K(-78.9%) |
| Sep 2003 | $96.20 K(-93.9%) | $96.20 K(-94.6%) |
| Jun 2003 | - | $1.77 M(+3.3%) |
| Mar 2003 | - | $1.72 M(+6.1%) |
| Dec 2002 | - | $1.62 M(+1.9%) |
| Sep 2002 | $1.59 M(+20.4%) | $1.59 M(+2.9%) |
| Jun 2002 | - | $1.54 M(+10.3%) |
| Mar 2002 | - | $1.40 M(+1.0%) |
| Dec 2001 | - | $1.38 M(+5.0%) |
| Sep 2001 | $1.32 M(+14.1%) | $1.32 M(+4.0%) |
| Jun 2001 | - | $1.27 M(+2.7%) |
| Mar 2001 | - | $1.23 M(+4.2%) |
| Dec 2000 | - | $1.18 M(+2.5%) |
| Sep 2000 | $1.16 M(+11.6%) | $1.16 M(-2.9%) |
| Jun 2000 | - | $1.19 M(+4.7%) |
| Mar 2000 | - | $1.14 M(+4.8%) |
| Dec 1999 | - | $1.08 M |
| Sep 1999 | $1.04 M(-63.5%) | - |
| Sep 1998 | $2.84 M(+5.8%) | - |
| Sep 1997 | $2.68 M | - |
FAQ
- What is Arrowhead Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual current liabilities year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly current liabilities year-on-year change?
What is Arrowhead Pharmaceuticals annual total current liabilities?
The current annual current liabilities of ARWR is $103.17 M
What is the all time high annual current liabilities for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual total current liabilities is $146.54 M
What is Arrowhead Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, ARWR annual total current liabilities has changed by -$2.29 M (-2.17%)
What is Arrowhead Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of ARWR is $103.17 M
What is the all time high quarterly current liabilities for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly total current liabilities is $195.43 M
What is Arrowhead Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, ARWR quarterly total current liabilities has changed by +$37.99 M (+58.29%)